1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. GAIN THERAPEUTICS INC
Gain Therapeutics Inc
XNAS: GANX
Download real time
1.67-0.02(-1.18%)
61.52% Fall from 52W High
644.9K
XNAS Volume

XNAS 06 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Gain Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Gain Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Gain Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Quarterly Net Profit Gain Therapeutics Inc Jun-2026 Quarterly Net Profit is $-5 Million which is growth of 19.5% YoY.

Gain Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
4.75.44.54.85.14.43.34.58.24.44.44.97.7
Operating Profit
-4.7-5.4-4.5-4.8-5.1-4.4-3.3-4.5-8.2-4.4-4.4-4.9-7.7
⌄
0.10.10.10.1000.10.10.10.10.10.10.1
Profit Before Tax
-4.6-5.4-4.5-4.7-5.7-4.4-3.3-4.5-8.1-4-4.7-4.7-7.7
Tax
0.10.20.10.60.10.10.500000
⌄
-4.7-5.6-4.5-5.3-5.8-4.5-3.8-4.5-8.1-4-4.7-4.7-7.7
Diluted NI Avail to Com Stockholders Ann.
-4.7-5.6-4.5-5.3-5.8-4.5-3.8-4.5-8.1-4-4.7-4.7-7.7
Basic EPS
-0.1-0.1-0.1-0.2-0.2-0.2-0.1-0.2-0.4-0.2-0.3-0.4-0.6
Diluted EPS After ExtraOrdinary
-0.1-0.1-0.1-0.2-0.2-0.2-0.1-0.2-0.4-0.2-0.3-0.4-0.6
Number Of Shares End
42.942.237.83530.328.727.726.519.2181512.712.4
Net Income Continuing Discontinued Operations
-4.7-5.6-4.5-5.3-5.8-4.5-3.8-4.5-8.1-4-4.7-4.7-7.7
Normalized Income
-4.7-5.5-4.5-5.3-5.3-4.5-3.8-4.4-8.1-4.2-4.4-4.8-7.6
Interest Income
------------0.1
Interest
-------------
Net Interest Income
0.10.10.10.1000.10.10.10.10.10.10.1
EBIT
-4.7-5.4-4.5-4.8-5.1-4.4-3.3-4.5-8.2-4.4-4.4-4.9-7.7
EBITDA
-4.7-5.3-4.4-4.8-5.1-4.4-3.3-4.4-8.2-4.4-4.4-4.9-7.7
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0000000000000
Profit From Continuing Operations
-4.7-5.6-4.5-5.3-5.8-4.5-3.8-4.5-8.1-4-4.7-4.7-7.7
Normalized EBITDA
-4.7-5.2-4.4-4.7-4.5-4.3-3.3-4.3-8.1-4.6-4-5-7.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Gain Therapeutics Inc competitor comparison and performance snapshot within industry

Gain Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue Gain Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Annual Net Profit Gain Therapeutics Inc Annual Net Profit is $-20 Million which is growth of 1.2% YoY.

Gain Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18
⌄
-
-
 0.10.10.2000
Cost Of Rev. Ann.
-
-
 --------
Gross Profit Ann.
-
-
 --------
Operating Exp. Ann.
1.5%
39.8%
19.318.720.422.317.9143.52.11.1
Operating Profit Ann.
-
-
-19.3-18.7-20.4-22.3-17.8-13.8-3.5-2.1-1
⌄
-20.6%
-
0.30.20.40.50.40-0-0.1
Other Exp. Ann.
-
-
 -0.80.1-0.4-0.1-0.1-0.1-0.1-0
PBT Ann.
-
-
-19.2-19.3-19.9-22.2-17.5-13.9-3.6-2.2-1.1
Tax Ann.
108%
-
0.90.90.50.10.1000
⌄
-
-
-20.1-20.2-20.4-22.3-17.6-13.9-3.6-2.2-1.1
Diluted NI Avail to Com Stockholders Ann.
-
-
-20.1-20.2-20.4-22.3-17.6-13.9-3.6-2.2-1.1
EPS Ann.
-
-
 -0.6-0.9-1.7-1.5-1.4-0.6-0.4-0.2
Diluted EPS Ann.
-
-
 -0.6-0.9-1.7-1.5-1.4-0.6-0.4-0.2
Number Of Shares End
47%
27.3%
 37.827.71511.911.911.3--
Total Exp. Ann.
1.5%
39.8%
 18.720.422.317.9143.52.11.1
Net Income Continuing Discontinued Operations Ann.
-
-
-20.1-20.2-20.4-22.3-17.6-13.9-3.6-2.2-1.1
Normalized Income Ann.
-
-
-19.9-19.5-20.5-21.9-17.5-13.8-3.5-2.2-1.1
Interest Income Ann.
-
-
 0.20.40.5-----
Interest Ann.
-
-
 --------
EBITDA Ann.
-
-
-19.2-18.6-20.3-22.2-17.7-13.8-3.5-2.1-1
Reconciled Cost Of Rev. Ann.
-
-
 --------
Reconciled Depr. Ann.
0%
-
0.10.10.10.10.100
Profit From Continuing Operations Ann.
-
-
-20.1-20.2-20.4-22.3-17.6-13.9-3.6-2.2-1.1
Normalized EBITDA Ann.
-
-
-19-17.8-20.4-21.7-17.6-13.7-3.4-2-1
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
-8.3%
2Y CAGR
-8.4%
3Y CAGR
1.5%
5Y CAGR
39.8%
7Y CAGR
49.9%
Operating Expenses Annual Cr is falling faster than historical averages.

Gain Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Gain Therapeutics Inc Dec-2025 Total Shareholders Fund is $19 Million which is growth of 152.9% YoY.

  • POSITIVE

    Total Assets Gain Therapeutics Inc Dec-2025 Total Assets is $23 Million which is growth of 88.2% YoY.

Gain Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18
⌄
-1.8%
18.9%
22.812.118.624.1399.60.7-
⌄
-6.1%
4.8%
4.34.865.24.23.41.1-
⌄
-0.5%
24.6%
18.67.312.618.934.86.2-0.5-
Total Capitalization Ann.
-0.9%
22.3%
18.97.71319.435.46.9-0.5-
Tangible Assets Ann.
-0.4%
24.4%
18.57.212.418.734.66.2-0.5-
Working Capital Ann.
3.6%
22.3%
18.97.712.81735.26.9-0.5
Invested Capital Ann.
-0.9%
22.5%
197.813.219.535.56.9-0.5-
Tangible Book Value Ann.
-0.4%
24.4%
18.57.212.418.734.66.2-0.5-
Borrowings Ann.
-18.6%
-11.6%
0.70.711.31.61.30.2-
Net Debt Ann.
-
-
--------
Share Issued Ann.
52.4%
30.1%
42.127.116.211.911.911.311.3-
Number Of Shares End
47%
27.3%
37.827.71511.911.911.3--
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
88.4%
2Y CAGR
10.7%
3Y CAGR
-1.8%
5Y CAGR
18.9%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
-12.8%
2Y CAGR
-17.5%
3Y CAGR
-6%
5Y CAGR
10.1%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
154.8%
2Y CAGR
21.5%
3Y CAGR
-0.5%
5Y CAGR
24.6%
Total ShareHolders Funds Annual growth is higher than historical averages.

Gain Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Gain Therapeutics Inc Book Value Per Share is $0 which is growth of 151.7% YoY.

  • NEUTRAL

    ROE Gain Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Gain Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18
RoA Ann. %
-
-
--132.83%-104.28%-55.77%-57.18%-69.71%-332.20%-
ROE Ann. %
-
-
--204.95%-141.57%-65.52%-67.73%-124.41%--
ROIC %
-
-
--42.7-43-21.2-8.5-22.2--
OPM Ann. %
-
-
---40,328.25%-12,687.92%-8,380.00%-12,047.96%-5,085.01%-4,989.42%
Inventory Turnover Ratio Ann.
-
-
--------
Asset Turnover Ann. %
-
-
--000.1-
Working Capital Turnover Ann.
-
-
0-0.1-
Quick Ratio Ann.
-
-
-2.93.44.914.53.60.4-
Current Ratio Ann.
-
-
-33.65.114.84.30.5-
Interest Coverage Ratio Ann.
-
-
--------
LT Debt To Equity Ann.
-
-
-0.10.10.100.2--
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Gain Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Gain Therapeutics Inc Cash From Operating Activity is $-18 Million which is growth of 2.2% YoY.

  • POSITIVE

    Net Cash Flow Gain Therapeutics Inc Net Cash Flow is $10 Million which is growth of 1228.9% YoY.

Gain Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18
⌄
-
-
-18.5-18.9-18.9-14.7-12.4-3.2-1.9-0.7
⌄
-
-
510.2-14.8-0.1-0-0-0
⌄
-
22.1%
28.51312.6-0.141.810.51.81
Cash Plus Cash Eqv. End Of Year Ann.
42%
22.7%
20.910.411.87.336.97.50.30.4
Net Increase In Cash Plus Cash Eqv.s Ann.
-
6.8%
10-0.94-29.629.37.2-0.10.2
Cash Plus Cash Eqv. Begin Of Year Ann.
-34.4%
103.2%
10.411.87.336.97.50.30.40.2
Income Tax Paid Supplemental Data Ann.
-
-
0.10.10.1-0
Interest Paid Supplemental Data Ann.
-
-
--------
Capex Ann.
-
-
--0-0-0.1-0.1-0-0-0
Issuance Of Capital Stock Ann.
-
20.1%
25.513.212.742.610.21.8
Issuance Of Debt Ann.
-
-
----0.71
Repayment Of Debt Ann.
-
-
-0.1-0.1-0.1-0.1-0---
Repurchase Of Capital Stock Ann.
-
-
--------
Free Cash Flow Ann.
-
-
-18.5-18.9-18.9-14.8-12.5-3.3-1.9-0.8
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Investing Act. Ann.
1Y CHG
-51%
Cash from Financing Act. Ann.
1Y CHG
119.2%
2Y CAGR
50.4%
5Y CAGR
22.1%
7Y CAGR
61.4%
Cash from Financing Annual Activity growth is stable compared to historical averages.
×